Esperion to Report First Quarter 2025 Financial Results on May 6

Company Overview - Esperion Therapeutics, Inc. is a commercial stage biopharmaceutical company focused on developing new medicines for unmet patient needs, particularly in cardiovascular disease [3] - The company has developed the only FDA-approved oral, once-daily, non-statin medications for patients with elevated low-density lipoprotein cholesterol (LDL-C) [3] - Esperion's medications are supported by the CLEAR Cardiovascular Outcomes Trial, which involved nearly 14,000 patients [3] Financial Reporting - Esperion will report its first quarter 2025 financial results before the market opens on May 6, 2025 [1] - Following the financial results release, management will host a webcast at 8:00 a.m. ET to discuss the results and provide business updates [1] Business Development - The company is advancing its pre-clinical pipeline and focusing on developing ATP citrate lyase inhibitors (ACLYi) [3] - New insights into ACLYi structure and function enable rational drug design for developing potent and specific inhibitors [3] - Esperion is evolving into a leading global biopharmaceutical company through commercial execution and international partnerships [4]